NCT05559905View on ClinicalTrials.gov

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

April 18, 2023

Study Completion Date

June 8, 2023

Conditions
Respiratory Syncytial Virus
Interventions
DRUG

Molnupiravir

Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.

DRUG

Placebo

Placebo capsule matched to molnupiravir taken twice daily by mouth.

BIOLOGICAL

RSV A Memphis 37b

RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).

Trial Locations (1)

E1 2AX

hVIVO Services ( Site 0001), London

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY